Experience of a Strategy Including CYP2C19 Preemptive Genotyping Followed by Therapeutic Drug Monitoring of Voriconazole in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation

• Egile Nagusiak: Irene García-García (Egilea), Irene Dapía (Egilea), Jaime Montserrat (Egilea), Lucía Martinez de Soto (Egilea), David Bueno (Egilea), Lucía Díaz (Egilea), Javier Queiruga (Egilea), Amelia Rodriguez Mariblanca (Egilea), Pilar Guerra-García (Egilea), Elena Ramirez (Egilea), Jesus Frías (Egilea), Antonio Pérez Martínez (Egilea), Antonio J. Carcas-Sansuan (Egilea), Alberto M. Borobia (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2021-10-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Many factors have been described to contribute to voriconazole (VCZ) interpatient variability in plasma concentrations, especially CYP2C19 genetic variability. In 2014, Hicks et al. presented data describing the correlation between VCZ plasma concentrations and CYP2C19 diplotypes in immunocompromise...